Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A) (HNRNPU) is a multifunctional nuclear protein encoded by the HNRNPU gene on human chromosome 1q44[1][3][7]. It binds both RNA and DNA, notably associating with scaffold/matrix-attachment regions of chromatin and forming complexes with heterogeneous nuclear RNA (hnRNA). In cell biology, HNRNPU is crucial for regulating alternative splicing, chromatin structure, transcription, DNA replication, genome stability, mitotic fidelity, and X chromosome inactivation[1][5][7]. Its central position in RNA and chromatin metabolism means mutations or deletions cause severe neurodevelopmental diseases, including epileptic encephalopathy and intellectual disability, and potentially contribute to cardiac and other diseases. There are no drugs directly targeting HNRNPU as its disruption results in loss of essential cellular functions and rapid cell death[4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A) (HNRNPU).